0 XP   0   0   0

Acacia Pharma Group PLC
Buy, Hold or Sell?

Should you buy, hold or sell Acacia Pharma Group PLC?

I guess you are interested in Acacia Pharma Group PLC. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

Let's analyse Acacia Pharma Group PLC

Let's start. I'm going to help you getting a better view of Acacia Pharma Group PLC. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

  1. Company's Financial Health
    A deep dive into the books. How are the numbers doing? Is Acacia Pharma Group PLC even making a profit? Is the company skyrocketing? Or is it sinking like the Titanic. The trend is your friend.
  2. Market Valuation
    Finally, you now have an insight of how Acacia Pharma Group PLC is doing in the market. If the company is worth buying. The latest step is to find out how other investors value Acacia Pharma Group PLC. The closing price on 2022-06-08 was €0.888 per share. Is the company over- or underpriced?
  3. Key Performance Indicators
    A total overlook on how the company is doing. Based on the (trends in) the key performance indicators.
Acacia Pharma Group PLC Daily Candlestick Chart
Acacia Pharma Group PLC Daily Candlestick Chart
Summary









1. Valuation of Acacia Pharma Group PLC




Current price per share

€0.89

2. Growth of Acacia Pharma Group PLC




Is Acacia Pharma Group PLC growing?

Current yearPrevious yearGrowGrow %
How rich?$25.8m$60.4m-$34.6m-133.8%

How much money is Acacia Pharma Group PLC making?

Current yearPrevious yearGrowGrow %
Making money-$67m-$33.4m-$33.5m-50.1%
Net Profit Margin-5,767.3%-15,866.4%--

How much money comes from the company's main activities?

3. Financial Health of Acacia Pharma Group PLC




Comparing to competitors in the Biotechnology industry




  Industry Rankings (Biotechnology)  


Richest
#795 / 1232

Most Revenue
#547 / 1232

Most Profit
#1098 / 1232

Most Efficient
#1096 / 1232


Summary

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is able to pay all its debts with equity.

1.1. Profitability of Acacia Pharma Group PLC.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Acacia Pharma Group PLC earns for each €1 of revenue.

  • Above 10% is considered healthy but always compare Acacia Pharma Group PLC to the Biotechnology industry mean.
  • A Net Profit Margin of -5,767.3% means that €-57.67 for each €1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Acacia Pharma Group PLC:

  • The MRQ is -5,767.3%. The company is making a huge loss. -2
  • The TTM is -5,767.3%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-5,767.3%TTM-5,767.3%0.0%
TTM-5,767.3%YOY-15,866.4%+10,099.0%
TTM-5,767.3%5Y-4,326.7%-1,440.6%
5Y-4,326.7%10Y-2,704.2%-1,622.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-5,767.3%-223.6%-5,543.7%
TTM-5,767.3%-281.7%-5,485.6%
YOY-15,866.4%-344.8%-15,521.6%
5Y-4,326.7%-450.1%-3,876.6%
10Y-2,704.2%-541.0%-2,163.2%
1.1.2. Return on Assets

Shows how efficient Acacia Pharma Group PLC is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Acacia Pharma Group PLC to the Biotechnology industry mean.
  • -108.2% Return on Assets means that Acacia Pharma Group PLC generated €-1.08 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Acacia Pharma Group PLC:

  • The MRQ is -108.2%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -108.2%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-108.2%TTM-108.2%0.0%
TTM-108.2%YOY-32.6%-75.6%
TTM-108.2%5Y-97.4%-10.8%
5Y-97.4%10Y-97.6%+0.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-108.2%-9.9%-98.3%
TTM-108.2%-8.9%-99.3%
YOY-32.6%-9.3%-23.3%
5Y-97.4%-11.7%-85.7%
10Y-97.6%-12.7%-84.9%
1.1.3. Return on Equity

Shows how efficient Acacia Pharma Group PLC is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Acacia Pharma Group PLC to the Biotechnology industry mean.
  • -259.3% Return on Equity means Acacia Pharma Group PLC generated €-2.59 for each €1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Acacia Pharma Group PLC:

  • The MRQ is -259.3%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -259.3%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-259.3%TTM-259.3%0.0%
TTM-259.3%YOY-55.3%-204.0%
TTM-259.3%5Y-184.0%-75.3%
5Y-184.0%10Y-115.0%-69.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-259.3%-12.0%-247.3%
TTM-259.3%-11.5%-247.8%
YOY-55.3%-10.8%-44.5%
5Y-184.0%-14.2%-169.8%
10Y-115.0%-15.2%-99.8%

1.2. Operating Efficiency of Acacia Pharma Group PLC.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Acacia Pharma Group PLC is operating .

  • Measures how much profit Acacia Pharma Group PLC makes for each €1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Acacia Pharma Group PLC to the Biotechnology industry mean.
  • An Operating Margin of -5,561.1% means the company generated €-55.61  for each €1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Acacia Pharma Group PLC:

  • The MRQ is -5,561.1%. The company is operating very inefficient. -2
  • The TTM is -5,561.1%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-5,561.1%TTM-5,561.1%0.0%
TTM-5,561.1%YOY-15,119.4%+9,558.3%
TTM-5,561.1%5Y-4,136.1%-1,425.0%
5Y-4,136.1%10Y-2,585.1%-1,551.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-5,561.1%-207.3%-5,353.8%
TTM-5,561.1%-271.0%-5,290.1%
YOY-15,119.4%-325.9%-14,793.5%
5Y-4,136.1%-454.0%-3,682.1%
10Y-2,585.1%-537.1%-2,048.0%
1.2.2. Operating Ratio

Measures how efficient Acacia Pharma Group PLC is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 46.77 means that the operating costs are €46.77 for each €1 in net sales.

Let's take a look of the Operating Ratio trends of Acacia Pharma Group PLC:

  • The MRQ is 46.768. The company is inefficient in keeping operating costs low. -1
  • The TTM is 46.768. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ46.768TTM46.7680.000
TTM46.768YOY147.545-100.777
TTM46.7685Y38.863+7.905
5Y38.86310Y24.289+14.573
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ46.7682.871+43.897
TTM46.7683.504+43.264
YOY147.5453.604+143.941
5Y38.8635.132+33.731
10Y24.2896.371+17.918

1.3. Liquidity of Acacia Pharma Group PLC.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Acacia Pharma Group PLC is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 3.79 means the company has €3.79 in assets for each €1 in short-term debts.

Let's take a look of the Current Ratio trends of Acacia Pharma Group PLC:

  • The MRQ is 3.787. The company is very able to pay all its short-term debts. +2
  • The TTM is 3.787. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ3.787TTM3.7870.000
TTM3.787YOY4.550-0.763
TTM3.7875Y3.576+0.211
5Y3.57610Y2.403+1.173
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.7875.117-1.330
TTM3.7875.755-1.968
YOY4.5505.854-1.304
5Y3.5766.511-2.935
10Y2.4036.222-3.819
1.3.2. Quick Ratio

Measures if Acacia Pharma Group PLC is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Acacia Pharma Group PLC to the Biotechnology industry mean.
  • A Quick Ratio of 2.95 means the company can pay off €2.95 for each €1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Acacia Pharma Group PLC:

  • The MRQ is 2.954. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 2.954. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ2.954TTM2.9540.000
TTM2.954YOY4.306-1.352
TTM2.9545Y3.358-0.404
5Y3.35810Y2.380+0.978
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.9544.284-1.330
TTM2.9544.664-1.710
YOY4.3064.787-0.481
5Y3.3585.218-1.860
10Y2.3805.182-2.802

1.4. Solvency of Acacia Pharma Group PLC.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Acacia Pharma Group PLC assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Acacia Pharma Group PLC to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.58 means that Acacia Pharma Group PLC assets are financed with 58.3% credit (debt) and the remaining percentage (100% - 58.3%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Acacia Pharma Group PLC:

  • The MRQ is 0.583. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.583. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.583TTM0.5830.000
TTM0.583YOY0.412+0.171
TTM0.5835Y1.620-1.038
5Y1.62010Y1.642-0.022
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.5830.278+0.305
TTM0.5830.277+0.306
YOY0.4120.306+0.106
5Y1.6200.367+1.253
10Y1.6420.403+1.239
1.4.2. Debt to Equity Ratio

Measures if Acacia Pharma Group PLC is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Acacia Pharma Group PLC to the Biotechnology industry mean.
  • A Debt to Equity ratio of 139.7% means that company has €1.40 debt for each €1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Acacia Pharma Group PLC:

  • The MRQ is 1.397. The company is able to pay all its debts with equity. +1
  • The TTM is 1.397. The company is able to pay all its debts with equity. +1
Trends
Current periodCompared to+/- 
MRQ1.397TTM1.3970.000
TTM1.397YOY0.700+0.697
TTM1.3975Y1.192+0.205
5Y1.19210Y0.745+0.447
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.3970.315+1.082
TTM1.3970.317+1.080
YOY0.7000.319+0.381
5Y1.1920.403+0.789
10Y0.7450.462+0.283

2. Market Valuation of Acacia Pharma Group PLC

2. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every €1 in earnings Acacia Pharma Group PLC generates.

  • Above 15 is considered overpriced but always compare Acacia Pharma Group PLC to the Biotechnology industry mean.
  • A PE ratio of -2.07 means the investor is paying €-2.07 for every €1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Acacia Pharma Group PLC:

  • The EOD is -1.442. Company is losing money. -2
  • The MRQ is -2.066. Company is losing money. -2
  • The TTM is -2.066. Company is losing money. -2
Trends
Current periodCompared to+/- 
EOD-1.442MRQ-2.066+0.624
MRQ-2.066TTM-2.0660.000
TTM-2.066YOY-8.608+6.541
TTM-2.0665Y-5.495+3.429
5Y-5.49510Y-3.435-2.061
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.442-8.986+7.544
MRQ-2.066-9.792+7.726
TTM-2.066-16.243+14.177
YOY-8.608-20.876+12.268
5Y-5.495-16.665+11.170
10Y-3.435-14.732+11.297
2.2. Price Earnings to Growth Ratio

Measures the predicted future growth of Acacia Pharma Group PLC.

  • Lower is better.
  • A PEG ratio of 1 means the market price of the stock and the expected future earnings are on par.

Let's take a look of the Price Earnings to Growth Ratio trends of Acacia Pharma Group PLC:

  • The MRQ is 586.171. Seems overpriced? -1
  • The TTM is 586.171. Seems overpriced? -1
Trends
Current periodCompared to+/- 
MRQ586.171TTM586.1710.000
TTM586.171YOY-16.114+602.284
TTM586.1715Y140.952+445.218
5Y140.95210Y140.9520.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ586.171-0.032+586.203
TTM586.1710.004+586.167
YOY-16.1140.016-16.130
5Y140.9520.006+140.946
10Y140.9520.003+140.949

2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Acacia Pharma Group PLC is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 5.36 means the investor is paying €5.36 for each €1 in book value.

Let's take a look of the Price to Book Ratio trends of Acacia Pharma Group PLC:

  • The EOD is 3.740. Neutral. Compare to industry.
  • The MRQ is 5.357. Seems overpriced? -1
  • The TTM is 5.357. Seems overpriced? -1
Trends
Current periodCompared to+/- 
EOD3.740MRQ5.357-1.617
MRQ5.357TTM5.3570.000
TTM5.357YOY4.764+0.593
TTM5.3575Y13.736-8.378
5Y13.73610Y8.585+5.151
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD3.7401.835+1.905
MRQ5.3572.006+3.351
TTM5.3572.774+2.583
YOY4.7643.453+1.311
5Y13.7362.713+11.023
10Y8.5852.402+6.183
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Acacia Pharma Group PLC compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.318-0.3180%0.515-162%0.074-529%0.030-1171%
Book Value Growth--0.4280.4280%13.911-97%3.575-88%2.354-82%
Book Value Per Share--0.2370.2370%0.555-57%0.167+42%0.081+194%
Book Value Per Share Growth--0.4280.4280%13.911-97%3.575-88%2.354-82%
Current Ratio--3.7873.7870%4.550-17%3.576+6%2.403+58%
Debt To Asset Ratio--0.5830.5830%0.412+42%1.620-64%1.642-65%
Debt To Equity Ratio--1.3971.3970%0.700+100%1.192+17%0.745+88%
Dividend Per Share----0%-0%-0%-0%
Eps---0.616-0.6160%-0.307-50%-0.276-55%-0.207-66%
Eps Growth---0.004-0.0040%0.534-101%0.019-119%0.019-119%
Free Cash Flow Per Share---0.409-0.4090%-0.233-43%-0.201-51%-0.179-56%
Free Cash Flow Per Share Growth--0.2430.2430%0.721-66%0.460-47%0.572-58%
Free Cash Flow To Equity Per Share---0.219-0.2190%0.281-178%0.021-1144%0.023-1060%
Free Cash Flow To Equity Per Share Growth---0.780-0.7800%3.475-122%1.464-153%1.293-160%
Gross Profit Margin--1.4771.4770%1.581-7%1.424+4%1.140+30%
Intrinsic Value_10Y_max--24.888--------
Intrinsic Value_10Y_min--20.382--------
Intrinsic Value_1Y_max--0.217--------
Intrinsic Value_1Y_min--0.211--------
Intrinsic Value_3Y_max--2.388--------
Intrinsic Value_3Y_min--2.224--------
Intrinsic Value_5Y_max--6.650--------
Intrinsic Value_5Y_min--5.964--------
Net Profit Margin---57.673-57.6730%-158.664+175%-43.267-25%-27.042-53%
Operating Margin---55.611-55.6110%-151.194+172%-41.361-26%-25.851-54%
Operating Ratio--46.76846.7680%147.545-68%38.863+20%24.289+93%
Pb Ratio3.740-43%5.3575.3570%4.764+12%13.736-61%8.585-38%
Pe Ratio-1.442+30%-2.066-2.0660%-8.608+317%-5.495+166%-3.435+66%
Peg Ratio--586.171586.1710%-16.114+103%140.952+316%140.952+316%
Price Per Share0.888-43%1.2721.2720%2.645-52%1.461-13%0.913+39%
Price To Total Gains Ratio-2.795+30%-4.003-4.0030%5.133-178%-1.849-54%-1.849-54%
Profit Growth---0.004-0.0040%0.534-101%0.502-101%0.606-101%
Quick Ratio--2.9542.9540%4.306-31%3.358-12%2.380+24%
Return On Assets---1.082-1.0820%-0.326-70%-0.974-10%-0.976-10%
Return On Equity---2.593-2.5930%-0.553-79%-1.840-29%-1.150-56%
Revenue Growth--5.5125.5120%--5.5120%5.5120%
Total Gains Per Share---0.318-0.3180%0.515-162%0.074-529%0.030-1171%
Total Gains Per Share Growth---0.617-0.6170%4.783-113%2.382-126%1.393-144%
Usd Book Value--25861468.34225861468.3420%60472065.283-57%18233505.731+42%8796938.491+194%
Usd Book Value Change Per Share---0.343-0.3430%0.556-162%0.080-529%0.032-1171%
Usd Book Value Per Share--0.2560.2560%0.599-57%0.181+42%0.087+194%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.664-0.6640%-0.332-50%-0.298-55%-0.223-66%
Usd Free Cash Flow---44562468.278-44562468.2780%-25358575.909-43%-21918294.944-51%-17074058.000-62%
Usd Free Cash Flow Per Share---0.441-0.4410%-0.251-43%-0.217-51%-0.193-56%
Usd Free Cash Flow To Equity Per Share---0.237-0.2370%0.303-178%0.023-1144%0.025-1060%
Usd Price Per Share0.958-43%1.3731.3730%2.854-52%1.577-13%0.986+39%
Usd Profit---67059656.225-67059656.2250%-33470840.730-50%-30278078.250-55%-23388538.752-65%
Usd Revenue--1162751.2921162751.2920%210954.878+451%274741.234+323%171713.271+577%
Usd Total Gains Per Share---0.343-0.3430%0.556-162%0.080-529%0.032-1171%
 EOD+3 -2MRQTTM+0 -0YOY+5 -345Y+9 -3010Y+10 -29

3.2. Fundamental Score

Let's check the fundamental score of Acacia Pharma Group PLC based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-1.442
Price to Book Ratio (EOD)Between0-13.740
Net Profit Margin (MRQ)Greater than0-57.673
Operating Margin (MRQ)Greater than0-55.611
Quick Ratio (MRQ)Greater than12.954
Current Ratio (MRQ)Greater than13.787
Debt to Asset Ratio (MRQ)Less than10.583
Debt to Equity Ratio (MRQ)Less than11.397
Return on Equity (MRQ)Greater than0.15-2.593
Return on Assets (MRQ)Greater than0.05-1.082
Total3/10 (30.0%)

3.3. Technical Score

Let's check the technical score of Acacia Pharma Group PLC based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5061.156
Ma 20Greater thanMa 500.835
Ma 50Greater thanMa 1000.815
Ma 100Greater thanMa 2001.075
OpenGreater thanClose0.878
Total2/5 (40.0%)



Latest Balance Sheet

Balance Sheet of 2021-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets62,014
Total Liabilities36,147
Total Stockholder Equity25,867
 As reported
Total Liabilities 36,147
Total Stockholder Equity+ 25,867
Total Assets = 62,014

Assets

Total Assets62,014
Total Current Assets31,223
Long-term Assets31,223
Total Current Assets
Cash And Cash Equivalents 21,615
Net Receivables 2,738
Inventory 6,870
Total Current Assets  (as reported)31,223
Total Current Assets  (calculated)31,223
+/-0
Long-term Assets
Property Plant Equipment 183
Intangible Assets 30,608
Long-term Assets  (as reported)30,791
Long-term Assets  (calculated)30,791
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities8,244
Long-term Liabilities27,903
Total Stockholder Equity25,867
Total Current Liabilities
Short-term Debt 122
Accounts payable 2,756
Other Current Liabilities 5,366
Total Current Liabilities  (as reported)8,244
Total Current Liabilities  (calculated)8,244
+/-0
Long-term Liabilities
Long term Debt 27,800
Capital Lease Obligations Min Short Term Debt103
Long-term Liabilities  (as reported)27,903
Long-term Liabilities  (calculated)27,903
+/-0
Total Stockholder Equity
Common Stock2,826
Retained Earnings -69,374
Other Stockholders Equity 92,415
Total Stockholder Equity (as reported)25,867
Total Stockholder Equity (calculated)25,867
+/-0
Other
Capital Stock2,826
Cash and Short Term Investments 21,615
Common Stock Shares Outstanding 79,867
Liabilities and Stockholders Equity 62,014
Net Debt 6,410
Net Invested Capital 53,667
Net Tangible Assets -4,741
Net Working Capital 22,979
Short Long Term Debt Total 28,025



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-312008-12-312007-12-31
> Total Assets 
1,058
914
2,101
1,429
2,173
868
4,645
4,046
11,799
12,605
4,829
38,513
18,669
102,835
62,014
62,014102,83518,66938,5134,82912,60511,7994,0464,6458682,1731,4292,1019141,058
   > Total Current Assets 
0
0
0
0
0
0
0
0
11,799
12,605
4,829
38,513
18,297
50,390
31,223
31,22350,39018,29738,5134,82912,60511,79900000000
       Cash And Cash Equivalents 
1,051
65
63
1,175
1,905
502
3,389
2,635
8,092
8,494
4,149
37,246
17,009
46,693
21,615
21,61546,69317,00937,2464,1498,4948,0922,6353,3895021,9051,17563651,051
       Short-term Investments 
0
600
1,655
0
0
0
0
0
0
0
0
0
0
0
0
0000000000001,6556000
       Net Receivables 
6
235
362
244
268
359
1,254
1,387
2,497
3,328
499
1,234
1,260
995
2,738
2,7389951,2601,2344993,3282,4971,3871,2543592682443622356
       Other Current Assets 
0
11
19
10
1
7
1
24
3,707
4,111
680
1,266
1,288
1,035
2,738
2,7381,0351,2881,2666804,1113,707241711019110
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
0
0
372
52,445
30,791
30,79152,445372000000000000
       Property Plant Equipment 
0
3
1
0
0
0
0
0
0
0
0
0
372
277
183
183277372000000000130
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
52,168
30,608
30,60852,1680000000000000
> Total Liabilities 
98
197
1,805
2,180
2,158
2,326
6,329
6,219
15,941
27,086
28,861
13,994
14,321
42,350
36,147
36,14742,35014,32113,99428,86127,08615,9416,2196,3292,3262,1582,1801,80519798
   > Total Current Liabilities 
98
197
858
2,180
2,158
2,326
6,329
1,358
15,941
20,951
28,861
5,152
9,620
11,075
8,244
8,24411,0759,6205,15228,86120,95115,9411,3586,3292,3262,1582,18085819798
       Short-term Debt 
0
0
0
0
0
0
0
0
4,286
3,342
12,455
424
5,453
5,417
122
1225,4175,45342412,4553,3424,28600000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
4,286
3,342
12,455
424
5,337
5,298
0
05,2985,33742412,4553,3424,28600000000
       Accounts payable 
48
85
57
76
135
75
293
558
4,359
6,339
1,351
1,129
2,653
1,144
2,756
2,7561,1442,6531,1291,3516,3394,3595582937513576578548
       Other Current Liabilities 
50
112
801
38
249
2,624
5,146
800
11,582
11,270
15,055
3,599
1,514
4,514
5,366
5,3664,5141,5143,59915,05511,27011,5828005,1462,6242493880111250
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
6,134
0
8,842
4,701
31,275
27,903
27,90331,2754,7018,84206,134000000000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
6,430
0
9,012
4,701
0
0
004,7019,01206,430000000000
> Total Stockholder Equity
960
717
296
0
16
0
0
0
-4,142
-14,481
-24,032
24,519
4,348
60,485
25,867
25,86760,4854,34824,519-24,032-14,481-4,142000160296717960
   Common Stock
52
66
66
66
66
1
1
1
1,004
865
947
1,354
1,619
2,518
2,826
2,8262,5181,6191,3549478651,0041116666666652
   Retained Earnings Total Equity000000000000000
   Accumulated Other Comprehensive Income 000000000000000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
5,837
5,837
70,947
75,588
0
0
0075,58870,9475,8375,837000000000
   Treasury Stock000000000000000
   Other Stockholders Equity 
0
0
0
0
0
0
0
0
-102,246
-79,555
-86,990
-16,852
-28,496
60,236
92,415
92,41560,236-28,496-16,852-86,990-79,555-102,24600000000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2021-12-31)

Gross Profit (+$)
totalRevenue1,163
Cost of Revenue-295
Gross Profit868868
 
Operating Income (+$)
Gross Profit868
Operating Expense-54,096
Operating Income-66,258-53,228
 
Operating Expense (+$)
Research Development4,070
Selling General Administrative18,031
Selling And Marketing Expenses31,995
Operating Expense54,09654,096
 
Net Interest Income (+$)
Interest Income2
Interest Expense-0
Net Interest Income-3,3362
 
Pretax Income (+$)
Operating Income-66,258
Net Interest Income-3,336
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-68,014-64,502
EBIT - interestExpense = -64,676
-68,014
-67,074
Interest Expense0
Earnings Before Interest and Taxes (ebit)-64,676-68,014
Earnings Before Interest and Taxes (ebitda)-56,487
 
After tax Income (+$)
Income Before Tax-68,014
Tax Provision--940
Net Income From Continuing Ops-67,074-67,074
Net Income-67,074
Net Income Applicable To Common Shares-67,074
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses54,391
Total Other Income/Expenses Net-1,7563,336
 

Comments

Join the conversation.

Leave a comment

Stay informed with my latest content.

Subscribe to my newsletter and receive an email as soon as I add content to PenkeTrading.com.


By clicking Register, you agree to the General Terms and Conditions.
Penke's Market Notifications
ENLT.TA
3 hours ago

I found you a STOCH Bearish Reversal Divergence on the daily chart of ENLT.TA.

ENLT.TA Daily Candlestick Chart
GBPEUR.FOREX
6 hours ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of GBPEUR.FOREX.

GBPEUR.FOREX Daily Candlestick Chart
NZDPHP.FOREX
6 hours ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of NZDPHP.FOREX.

NZDPHP.FOREX Daily Candlestick Chart
NZDIDR.FOREX
6 hours ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of NZDIDR.FOREX.

NZDIDR.FOREX Daily Candlestick Chart
MYRGBP.FOREX
6 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of MYRGBP.FOREX.

MYRGBP.FOREX Daily Candlestick Chart
GBPMYR.FOREX
6 hours ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of GBPMYR.FOREX.

GBPMYR.FOREX Daily Candlestick Chart
GBPIDR.FOREX
6 hours ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of GBPIDR.FOREX.

GBPIDR.FOREX Daily Candlestick Chart
SGDGBP.FOREX
6 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of SGDGBP.FOREX.

SGDGBP.FOREX Daily Candlestick Chart
GBPSGD.FOREX
6 hours ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of GBPSGD.FOREX.

GBPSGD.FOREX Daily Candlestick Chart
CADNOK.FOREX
6 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of CADNOK.FOREX.

CADNOK.FOREX Daily Candlestick Chart
SVRT.TA
7 hours ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of SVRT.TA.

SVRT.TA Daily Candlestick Chart
PHTM.TA
7 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of PHTM.TA.

PHTM.TA Daily Candlestick Chart
NICE.TA
7 hours ago

I found you a Golden Cross on the daily chart of NICE.TA.

NICE.TA Daily Candlestick Chart
NFTA.TA
7 hours ago

I found you a MACD Bearish Hidden Divergence on the daily chart of NFTA.TA.

NFTA.TA Daily Candlestick Chart
ICB.TA
7 hours ago

I found you a STOCH Bullish Hidden Divergence on the daily chart of ICB.TA.

ICB.TA Daily Candlestick Chart
FRSX.TA
7 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of FRSX.TA.

FRSX.TA Daily Candlestick Chart
DCMA.TA
7 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of DCMA.TA.

DCMA.TA Daily Candlestick Chart
ARD.TA
7 hours ago

I found you a Death Cross on the daily chart of ARD.TA.

ARD.TA Daily Candlestick Chart
MCRNT.TA
9 hours ago

I found you a STOCH Bearish Reversal Divergence on the daily chart of MCRNT.TA.

MCRNT.TA Daily Candlestick Chart